ÌÇÐÄ̽»¨

What are tobacco Heated Products?

Ìý

Heated Products* (HPs) are devices that use heatÌý to generate a nicotine-containing aerosol, which the user inhales. This category includes Tobacco Heated Products (THP) and Herbal Products for Heating (HPH). Within HPs, because the tobacco or herbal substrate is heated instead of burned, the resulting aerosol comprises mainly water, glycerol, nicotine and flavours – different to cigarette smoke.Ìý

Our flagship HP brand, glo, comprises an electronic handheld device that contains a lithium-ion battery which powers a heating chamber. A specially designed rod containing homogenised tobacco, called a Neostik, is then inserted into the device.

The scientific evidence

In a cigarette, the tobacco is burned by combustion at temperatures over 900ºC, releasing a highly complex mixture of gases, particles and compounds and leaving behind a grey ash.

In contrast, HPs heat natural material, including tobacco or other ingredients like rooibos, to much lower temperatures (below 400ºC). Due to the heating, as opposed to burning, HPs are considered reduced risk* compared to continued smoking for those who switch completely.

By not burning the tobacco this dramatically changes the composition of the aerosol. Comparing cigarette smoke with glo aerosol, the weight of evidence shows that the levels of toxicants were reduced on average by 90-95%.*†

To date, most research has been conducted by industry scientists, but an increasing number of independent reports are broadly aligned with these findings and support the role of THPs as a less risky*† alternative to smoking.

In 2022, we published the results of a year-long study which showed that smokers switching exclusively to glo, achieved significant and sustained improvements in several indicators of potential harm compared to those who continued to smoke.

The full results, which were published in Internal and Emergency Medicine, build upon the favourable changes reported at three and six months. The improvements observed were sustained over the 12 months of the study, adding to the weight of evidence that supports glo as a less risky* alternative for adult smokers who would not otherwise quit.

The results from this study are the most important data we have ever generated about glo and for the THP category in general. This real-world study allows us to assess the changes that adult smokers switching exclusively to glo experience, by assessing early indicators of potential harm associated with disease development. It provides much needed new evidence about the size of the change and durability of the effect switching completely to glo can have, and reinforces glo’s potential as a reduced-risk product*.